Changeflow GovPing Pharma & Healthcare Relief Efficacy of Lidocaine Versus Morphine fo...
Routine Notice Added Final

Relief Efficacy of Lidocaine Versus Morphine for Acute Renal Colic in the Emergency Department

Favicon for changeflow.com ClinicalTrials.gov Studies
Detected
Email

Summary

NIH has registered a new clinical trial (NCT07536594) on ClinicalTrials.gov comparing intravenous lidocaine to morphine for acute renal colic pain management in emergency departments. The trial aims to address the opioid epidemic by investigating whether lidocaine can serve as an effective non-opioid alternative for pain management. Researchers plan to recruit a diverse population to build on preliminary evidence from a 2012 Iranian study.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH has registered a new clinical trial (NCT07536594) on ClinicalTrials.gov comparing lidocaine versus morphine for acute renal colic pain in emergency departments. The trial aims to address the opioid epidemic by investigating non-opioid pain management alternatives. Researchers will recruit 140 participants in a randomized controlled trial setting, building on preliminary evidence from a 2012 Iranian study that found 90% success in the lidocaine group versus 70% in the morphine group.

Healthcare providers and clinical investigators conducting pain management research should be aware of this trial, which may inform future clinical practice regarding non-opioid analgesics for acute renal colic. The study's focus on reducing unnecessary opioid prescriptions aligns with broader public health initiatives to combat opioid use disorder.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Relief Efficacy of Lidocaine Versus Morphine for Acute Renal Colic in the Emergency Department

N/A NCT07536594 Kind: NA Apr 17, 2026

Abstract

The opioid epidemic continues to be a major public health crisis in the United States. According to the Center for Disease Control, approximately 8 million Americans reported misusing prescription opioids in 2023, with over 5 million Americans reporting that they suffer from opioid use disorder. The United States government estimates that 105,000 people died from drug overdose in 2023, and approximately 80,000 of those deaths can be attributed to opioids (~76%). In acknowledgement of the opioid crisis, we wish to contribute to ongoing efforts to reduce unnecessary and excessive opioid prescription.

In 2012, researchers in Iran published a randomized controlled trial comparing intravenous (IV) lidocaine to IV morphine for acute renal colic, reporting that 90% patients responded "successfully" in the lidocaine group versus 70% in the morphine group. They also concluded that there was a statistically significant difference between pain scores between the two groups at all time points, favoring the lidocaine group. However, the study was conducted at a single emergency department in Tabriz, Iran, with a relatively homogenous patient population, and the researchers did not explicitly define their primary outcome variable for what constituted a "successful" response in the treatment groups. The investigators of this study aim to build upon this preliminary evidence by recruiting a more diverse population to improve generalizability and by predefining pain-reduction thresholds ...

Conditions: Renal Colic, Kidney Stones, Urolithiasis, Hypocitraturia, Opioid Use During Medical Care

Interventions: Lidocaine, Morphine 0,1 mg/kg

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07536594

Who this affects

Applies to
Healthcare providers Clinical investigators Patients
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial conduct Drug comparison research Pain management research
Geographic scope
United States US

Taxonomy

Primary area
Public Health
Operational domain
Clinical Operations
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!